Professor, Medicine - Blood and Marrow Transplantation, Stanford University Medical Center
Hematology
Dr. Robert S. Negrin, MD
|
|
Give Review
Robert S. Negrin, MD is an expert in the field of Hematology. He studied medicine at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School has a rank of 1 in research and a 12 in primary care He over the years received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Dr. Robert S. Negrin has written publications. He has 93 publications published with PubMed. The lastest paper is: 'NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment.' Robert Negrin is registered with Medicare.
Publications
- Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.
- ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.
- Third party CD4+ invariant natural killer T cells protect from murine GVHD lethality.
- Engraftment of Embryonic Stem Cells and Differentiated Progeny by Host Conditioning with Total Lymphoid Irradiation and Regulatory T Cells.
- CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells.
- Identification of Orai1 Channel Inhibitors by Using Minimal Functional Domains to Screen Small Molecule Microarrays.
- Single dose of autologous apoptotic cells preceding transplantation significantly enhances survival in lethal murine graft versus host models.
- Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion.
- Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with Myelodysplastic syndromes and myeloproliferative neopla...
- Introduction to the review series on 'Advances in hematopoietic cell transplantation'
- A killer choice for cancer immunotherapy.
- Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations.
- Donor hematopoiesis in mice following total lymphoid irradiation requires host T regulatory cells for durable engraftment.
- Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.
- Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation.
- IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease Following Bone Marrow Transplantation.
- A distinct evolution of the T cell repertoire categorizes treatment refractory gastrointestinal Acute graft-versus-host disease.
- Karl georg blume, M.D.
- Cancer vaccines and T cell therapy.
- Rapid development of exhaustion and downregulation of eomesodermin limits the anti-tumor activity of adoptively transferred murine natural killer cells.
- Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells.
- Rapamycin and IL-2 reduce lethal Acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
- Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation.
- CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antiLymphoma activity without GVHD.
- Low doses of natural killer T cells provide protection from Acute graft-versus-host disease via an IL-4-dependent mechanism.
- Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells.
- Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation.
- CXCL12 mediates immunosuppression in the Lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.
- Definition of an enhanced immune cell therapy in mice that can target stem-like Lymphoma cells.
- Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complet...
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory...
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
- Biology and clinical effects of natural killer cells in allogeneic transplantation.
- Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced Neutropenia after autologous transplantation in patients with non-Hodg...
- Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
- Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.
- TLI and ATG conditioning with low risk of graft-versus-host Disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and un...
- Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses.
- Glycogen synthase kinase 3beta missplicing contributes to Leukemia stem cell generation.
- Follicular Lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.
- Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoiet...
- Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo.
- In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.
- Long-term remission of Philadelphia chromosome-positive Acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a...
- Long-term results of autologous hematopoietic cell transplantation for peripheral T cell Lymphoma: the Stanford experience.
- Prevention of Acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs.
- Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy.
- The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation.
- Immune regulatory networks in the post-transplant setting.
- Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.
- Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-Leukemia activity.
- Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during Acute graft-versus-host disease.
- A novel technique for the enrichment of primary ovarian cancer cells.
- CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells.
- In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host Disease following allogeneic transplantation.
- Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of Acute graft-versus-host disease.
- The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid Leukemia.
- Methods for imaging cell fates in hematopoiesis.
- Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
- Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin Lymphoma.
- Synergistic antitumor effects of immune cell-viral biotherapy.
- Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
- Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
- Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation.
- Protective conditioning for Acute graft-versus-host disease.
- In vivo analyses of early events in Acute graft-versus-host disease reveal sequential infiltration of T-cell subsets.
- Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation.
- Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells.
- Engraftment and survival following reduced-intensity allogeneic Peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.
- A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin Disease and non-Hodgkin lymphoma.
- Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal Acute GVHD.
- Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid Leukemia.
- Rapamycin (sirolimus) for treatment of Chronic graft-versus-host disease.
- Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system.
- Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin Lymphoma.
- Shifting foci of hematopoiesis during reconstitution from single stem cells.
- Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome.
- Evaluation of effector cell fate and function by in vivo bioluminescence imaging.
- CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host Disease after bone marrow transplantation.
- Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
- Revealing Lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.
- Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
- Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice.
- Understanding immune cell trafficking patterns via in vivo bioluminescence imaging.
- Role of lymphocyte activation gene-3 (lag-3) in conventional and regulatory T cell function in allogeneic transplantation.
- European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with Acute myeloid leukemia undergoing allogeneic hematopoiet...
- Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.
- Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization.
- NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment.
Schools
Harvard Medical School
Stanford University Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Hodgkin's Disease
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Stanford University -
Harvard Medical School
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1285791756 | |
| NPPES Provider LastName | NEGRIN | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 94305 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology | |
| Total Claim Count | 110.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285791756 |
| Last Name Of The Provider | NEGRIN |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Sharon M. Geaghan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruno C. Medeiros, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert Kaizer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sally Arai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott D. Boyd, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Chan, MD |
|
|
Dr. Nam Q. Bui, MD |